Navigation Links
SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
Date:3/12/2008

Conference call scheduled today at 8:00 a.m. Pacific Time

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced financial results for the year and fourth quarter ended December 31, 2007. For the full year 2007, the Company posted total revenues of $34.7 million and a net loss of $16.0 million, or $1.01 per share. For the quarter ended December 31, 2007, the Company posted total revenues of $7.7 million and a net loss of $6.1 million, or $0.35 per share. Cash and cash equivalents totaled $39.0 million at December 31, 2007 compared to $33.9 million at December 31, 2006.

2007 Overview and Pipeline Update

-- SGX523: In November 2007, the Company submitted an investigational new

drug application (IND) to the FDA, only ten months after designating

this small-molecule MET receptor tyrosine kinase inhibitor as a

development candidate. Two Phase I studies were initiated in January

2008 in subjects with solid tumors; patient enrollment is ongoing.

-- SGX126: Expanding the MET program, in November 2007, SGX designated

SGX126 as its next MET development candidate. Like SGX523 and the

Company's BCR-ABL inhibitors, this development candidate was discovered

using the Company's FAST(TM) platform. This orally-bioavailable small

molecule shows potent and selective in vitro and in vivo activity with

a profile complementary to that of SGX523.

-- SGX393: This selective, orally-bioavailable BCR-ABL inhibitor is

currently in IND enabling studies and, pending successful completion,

an IND submission is planned during the second quarter of 2008. SGX393

is a potent inhibi financial measures facilitate comparison of operating results across reporting periods, and uses these non-GAAP financial measures when evaluating its financial results, as well as for internal planning and forecasting purposes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP.

tor of the T315I mutant (as well as other resistant

mutants and wild-type BCR-ABL) and is likely most applicable to

relapsed/refractory chronic myelogenous leukemia (CML).

-- The research activities conducted under the Company's collaboration

with Novartis have resulted in the identification of a number of

promising BCR-ABL inhibitors targeting the front-line CML population.

The collaborative research phase is due to end in late March 2008 in

accordance with the agreement and, thereafter, Novartis is responsible

for further development of drug candidates identified under the

collaboration. At this time, an IND for a drug candidate under the

collaboration is not anticipated in 2008.

-- In addition to the inhibitors targeting the front-line CML population,

the Company is currently pursuing a portfolio of drug discovery targets

which have been implicated in various human cancers. The goal for the

Company's FAST(TM) drug discovery program is to nominate two new

development candidates by year end leading to IND submission in 2009.

-- In November 2007, the Company completed a private placement financing

providing net proceeds of $23.2 million.

"We began 2008 by initiating clinical development of our first internally developed oncology drug candidate, SGX523, now enrolling subjects in two phase I studies," said Mike Grey, President and Chief Executive Officer of SGX Pharmaceuticals. "After SGX523, we have SGX393 from our BCR-ABL program, and SGX126, also from our MET program, preparing for IND submissions in 2008. In addition to these compounds, our drug discovery portfolio is focused on multiple oncology targets. We are very pleased with our accomplishments in 2007 and excited by the many clinical, preclinical and discovery-stage opportunities in 2008 and beyond."

Financial Results for the Full Year and Fourth Quarter Ended December 31, 2007

Total revenues for the year ended December 31, 2007 were $34.7 million, compared to $27.8 million for the year ended December 31, 2006. Total revenues in the fourth quarter of 2007 were $7.7 million, compared to $8.4 million in the fourth quarter of 2006.

The increased revenue of $6.9 million for 2007, compared to 2006, is primarily attributable to additional revenues earned through our Novartis collaboration, together with the achievement of a milestone, and additional services provided under other collaborations and commercial agreements. This increase also reflects the recognition of revenue in the first quarter of 2007 related to the reimbursement of indirect costs incurred on grant research since the commencement of the grant in July 2005.

The $0.7 million decrease in revenue for the fourth quarter of 2007, compared to the fourth quarter of 2006, reflects higher Novartis direct development costs, thereby reducing the amount of revenue recognized for out-of-pocket reimbursements, offset by revenue recognized for additional services provided under other collaborations and commercial agreements.

Research and development expenses totaled $42.2 million for the year ended December 31, 2007, compared to $46.9 million for the year ended December 31, 2006. Research and development expenses totaled $11.2 million for the fourth quarter of 2007, compared to $11.4 million in the same period of 2006. The decrease of $4.7 million in 2007, compared to 2006, is primarily attributable to reduced expenditures for outside services in connection with the MET and BCR-ABL programs, reduced payments to subcontractors performing services in connection with our grant research efforts and lower depreciation expense. The decrease of $0.2 million for the fourth quarter of 2007, as compared to the fourth quarter of 2006, was primarily attributable to lower depreciation expense.

General and administrative expenses totaled $8.6 million for the year ended December 31, 2007, compared to $9.6 million for the year ended December 31, 2006. General and administrative expenses totaled $2.2 million for the fourth quarters of both 2007 and 2006. The decrease in general and administrative expenses in 2007, compared to 2006, is primarily attributable to lower stock-based compensation expense for option and restricted stock grants.

SGX reported a net loss applicable to common stockholders for the full year and fourth quarter ended December 31, 2007 of $16.0 million, or $1.01 per share, and $6.1 million, or $0.35 per share, respectively. This compares with a net loss applicable to common stockholders for the full year and fourth quarter ended December 31, 2006 of $28.1 million, or $2.03 per share, and $4.9 million, or $0.32 per share, respectively.

The decrease in the net loss in 2007, compared to 2006, is primarily attributable to an increase in revenues in connection with the Novartis collaboration, an increase in revenue recognized in connection with the reimbursement of indirect costs related to grant-related activities, a decrease in non-cash related operating expenditures, and a decrease in expenditures to subcontractors performing services in connection with our grant research efforts. The increase in the net loss for the fourth quarter of 2007, compared to the fourth quarter of 2006, is primarily attributable to lower revenues earned in connection with our collaboration with Novartis.

For 2008, the Company projects a net cash burn of approximately $19 -- $21 million before any cash inflows in connection with a potential collaboration around the Company's MET program.

Conference Call and Webcast

The Company will hold a conference call at 8:00 a.m. Pacific Time today March 12, 2008, to discuss these results and business highlights. Interested participants and investors may access the teleconference call by dialing 800-573-4752 (U.S./Canada) or 617-224-4324 (international), participant code 20358556. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 55640708.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as SGX523, a MET kinase inhibitor currently in Phase 1 clinical studies, next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and a portfolio of inhibitors of various oncology targets. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to research and development programs, net cash burn and plans for 2008 and beyond, expectations regarding the timing of the filing of INDs and commencement and success of IND enabling activities and preclinical and clinical studies, partnership opportunities, the potential of the Company's inhibitors as treatments for certain cancers, partnering opportunities for the Company's research and development programs, including any potential collaborations around the Company's MET program and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence IND enabling activities or preclinical or clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the initiation, implementation and conclusion of its collaborations, cash generated or used in connection with new or existing collaborations, the failure to successfully complete collaborations or partnerships, the partnering of its research and development programs, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the level of resources that its collaborative partners devote to development of its product candidates, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, the Company's quarterly report on Form 10-Q for the three and nine months ended September 30, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

SGX PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaborations and commercial

agreements $5,554 $6,714 $22,367 $19,906

Grants 2,125 1,723 12,372 7,874

Total revenue 7,679 8,437 34,739 27,780

Expenses:

Research and development 11,242 11,352 42,249 46,942

General and administrative 2,233 2,168 8,642 9,588

Total operating expenses 13,475 13,520 50,891 56,530

Loss from operations (5,796) (5,083) (16,152) (28,750)

Interest income (expense), net (326) 198 145 698

Net loss (6,122) (4,885) (16,007) (28,052)

Accretion to redemption value of

redeemable

convertible preferred stock - - - (49)

Net loss attributable to common

stockholders $(6,122) $(4,885) $(16,007) $(28,101)

Basic and diluted net loss per share

attributable

to common stockholders $(0.35) $(0.32) $(1.01) $(2.03)

Shares used to compute basic and

diluted net

loss per share attributable to

common stockholders 17,707 15,152 15,915 13,814

Three Months Ended Three Months Ended

December 31, 2007 (1) December 31, 2006 (1)

Stock- Stock-

based Reported based Reported

non- compensation GAAP non- compensation GAAP

GAAP expense results GAAP expense results

Net loss

attributable

to common

stockholders $(5,532) $(590) $(6,122) $(4,126) $(759) $(4,885)

Basic and

diluted net

loss per

share

attributable

to common

stockholders $(0.32) $(0.02) $(0.35) $(0.27) $(0.05) $(0.32)

Research and

development

expenses $10,922 $320 $11,242 $11,064 $288 $11,352

General and

administrative

expenses $1,963 $270 $2,233 $1,697 $471 $2,168

Year Ended Year Ended

December 31, 2007 (1) December 31, 2006 (1)

Stock- Stock-

based Reported based Reported

non- compensation GAAP non- compensation GAAP

GAAP expense results GAAP expense results

Net loss

attributable

to common

stockholders $(12,637) $(3,370) $(16,007) $(23,532) $(4,569) $(28,101)

Basic and

diluted net

loss per

share

attributable

to common

stockholders $(0.79) $(0.21) $(1.01) $(1.70) $(0.33) $(2.03)

Research and

development

expenses $40,519 $1,730 $42,249 $44,818 $2,124 $46,942

General and

administrative

expenses $7,002 $1,640 $8,642 $7,143 $2,445 $9,588

SGX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

December 31, December 31,

2007 2006

Assets

Cash, cash equivalents and short-

term investments $38,990 $33,877

Accounts receivable 2,706 3,532

Other current assets 1,187 1,616

Property and equipment, net 3,889 5,435

Other assets 4,284 4,004

Total assets $51,056 $48,464

Liabilities and stockholder's equity

Current liabilities $24,991 $21,762

Deferred revenue, long-term 1,042 13,023

Other liabilities, net of current

portion - 66

Stockholder's equity 25,023 13,613

Total liabilities and

stockholder's equity $51,056 $48,464

1) In addition to disclosing financial results calculated in accordance with generally accepted accounting principles (GAAP), this table contains non-GAAP financial measures that exclude the effect of non-cash stock compensation expense. The Company believes that the presentation of results excluding non-cash stock compensation expense provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results. The Company believes these non-GAAP
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
2. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
3. Drinking Water Association Discusses Pharmaceuticals in Water
4. Genesis Pharmaceuticals Changes Auditors
5. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
6. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
7. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
8. NPS Pharmaceuticals to Report 2007 Financial Results
9. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
10. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac ... significant negative impact on long-term patient survival, reports a team of UPMC researchers ... this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical information ...
(Date:5/26/2016)... ... 26, 2016 , ... Dr. James Maisel will present on ... Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. The ... Group of New York , is a Board Certified ophthalmologist who completed his ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... multitude of activities from daily practices, arts & crafts, discussions, and games all ... East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, collegiate sport yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... 2016 Open Access Journal ... Elsevier , a world-leading provider of ... announced the launch of Clinical Neurophysiology ... focuses on clinical practice issues in clinical neurophysiology. The ... normal values and didactic reviews. It is an official ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology: